This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month marketwatch.com
- Dozens of people sue GLP-1 drug companies over alleged vision loss aljazeera.com
- Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point? finance.yahoo.com